HIGHLIGHTS
- who: September and collaborators from the Alam, Malaysia Fujian Medical University, China have published the research work: Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair pro cient advanced endometrial cancer in China, in the Journal: (JOURNAL) of 11/06/2018
- what: The aim of the Frontiers in Pharmacology The Kaplan-Meier survival curve, generated from the study 309-KEYNOTE -775 trial using Get Data Graph Digitizer 2.25, was used to calculate the probability of transition between the three health stages.
- how: The authors . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.